ミノキシジル：休止期脱毛症

合計20,927名の参加者を対象とした52件の研究（メタアナリシス1件、RCT 1件を含む）に基づく。52件中39件の研究で肯定的な効果が示されている。

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dtelogen\u002Deffluvium'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Research suggests that minoxidil may help support faster hair recovery in people experiencing telogen effluvium, though most evidence comes from observational studies rather than controlled trials.

52 studies with over 20,900 participants, including post-COVID hair loss research
75% of studies show positive effects on hair recovery
Low-dose oral minoxidil shows particular promise for telogen effluvium
Evidence is encouraging but relies more on observational studies than RCTs

Key Study Findings

Review

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.

Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

review

Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.

Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo 効果: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None

clinical trial n=12 24 weeks Open-label

Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial.

Dose: 5% topical minoxidil lotion 1mL applied to entire scalp twice daily vs: Placebo 効果: Terminal hair count increased by 12.55±4.99 hairs/cm2 at week 4 and 11.20±4.79 hairs/cm2 at week 12; None

review

The Use of Light-Based Therapies in the Treatment of Alopecia.

Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri vs: Placebo 効果: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None

Review

Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven …

Dose: None vs: Placebo 効果: None None

Review

Research progress in the treatment of non-scarring alopecia: mechanism and treatment.

Dose: None vs: Placebo 効果: None None

Key Statistics

研究数

20942

参加者数

↑

Positive

グレード

Referenced Papers

Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. Review

American journal of … 2026 1 件の引用

Cardiovascular safety of low-dose oral minoxidil in nonscarring alopecia: A multicenter population-based cohort study using TriNetX. Other

Journal of the … 2026 1 件の引用

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. Review

American journal of … 2026

A Scoping Review of Exosome Delivery Applications in Hair Loss. Review

Cureus 2025 7 件の引用

Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation. Review

Cureus 2025 2 件の引用

Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. Review

Aesthetic plastic surgery 2025 2 件の引用

Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Review

Frontiers in pharmacology 2025 2 件の引用

Minoxidil Promotes Hair Growth in a Mouse Model of Telogen Effluvium Induced by Lipopolysaccharide. Other

The Journal of … 2025

Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review. Case Report

Cureus 2025

Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. Review

Journal of drugs … 2025

Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study. Other

Telemedicine reports 2025

Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial. Other

The Journal of … 2025

The Use of Light-Based Therapies in the Treatment of Alopecia. Review

Journal of cosmetic … 2025

Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients. Other

Actas dermo-sifiliograficas 2025

Status of research on the development and regeneration of hair follicles. Review

International journal of … 2024 39 件の引用

Dissolvable microneedles loaded ginsenoside Rg3 liposome: a transdermal delivery approach for alopecia treatment. Other

Regenerative biomaterials 2024 18 件の引用

Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and NonCicatricial Alopecia: A Systematic Review Study. Review

Health science reports 2024 14 件の引用

Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. Other

International journal of … 2024 6 件の引用

Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. Other

Indian journal of … 2024 4 件の引用

Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia. Review

Life (Basel, Switzerland) 2024 4 件の引用

Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. Other

International journal of … 2024 3 件の引用

Assessing low-dose oral minoxidil efficacy in androgenetic alopecia: a comparative study of AGA and AGA unmasked by telogen effluvium. Other

Archives of dermatological … 2024 2 件の引用

Oral minoxidil use in androgenetic alopecia and telogen effluvium. Other

Archives of dermatological … 2023 16 件の引用

Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … Other

Journal of cosmetic … 2023 6 件の引用

Hair loss after drug reaction with eosinophilia and systemic symptoms (DRESS): A multicentric retrospective case series. Other

The Journal of … 2023 3 件の引用

Characteristics of hair loss in COVID-19 patients in Thailand. Other

Medicine 2023 3 件の引用

Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … Other

Italian journal of … 2023 3 件の引用

Minoxidil: a comprehensive review. Review

The Journal of … 2022 170 件の引用

Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. Other

Journal of the … 2022 17 件の引用

Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better … Review

The Journal of … 2022 16 件の引用

Valproate-associated hair abnormalities: Pathophysiology and management strategies. Review

Human psychopharmacology 2022 7 件の引用

COVID-19-induced Scalp Alopecia Treated Effectively with Stem Cell Serum. Case Report

Plastic and reconstructive … 2022 1 件の引用

Oral minoxidil treatment for hair loss: A review of efficacy and safety. Review

Journal of the … 2021 203 件の引用

Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. Review

Journal of the … 2021 53 件の引用

Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. Systematic Review

Dermatologic therapy 2021 52 件の引用

Telogen Effluvium - a review of the science and current obstacles. Review

Journal of dermatological … 2021 51 件の引用

Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial. Other

EClinicalMedicine 2021 14 件の引用

Telogen Effluvium: A Review of the Literature. Review

Cureus 2020 162 件の引用

Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Systematic Review

International journal of … 2020 58 件の引用

Off-Label Use of Topical Minoxidil in Alopecia: A Review. Review

American journal of … 2019 84 件の引用

Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Observational

International journal of … 2018 142 件の引用

Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells: Possible Implications Against Nonscarring Alopecia. Other

Medical archives (Sarajevo, … 2018 16 件の引用

Hair Loss: Common Causes and Treatment. Other

American family physician 2017 141 件の引用

Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. Other

F1000Research 2017 65 件の引用

Scalp Psoriasiform Contact Dermatitis with Acute Telogen Effluvium due to Topical Minoxidil Treatment. Other

Skin appendage disorders 2016 19 件の引用

Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. Review

The Medical clinics … 2015 66 件の引用

Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. Other

Seminars in cutaneous … 2015 27 件の引用

Hair loss in women. Review

Clinical obstetrics and … 2015 9 件の引用

Telogen effluvium revisited. Review

Giornale italiano di … 2014 18 件の引用

Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. Other

Dermatologic therapy 2014 13 件の引用

Female pattern hair loss. Review

International journal of … 2013 61 件の引用

Female pattern hair loss. Review

Indian journal of … 2013 16 件の引用

Diffuse hair loss in an adult female: approach to diagnosis and management. Review

Indian journal of … 2009 109 件の引用

Diagnosing and treating hair loss. Review

American family physician 2009

Adolescent hair loss. Review

Current opinion in … 2008 31 件の引用

Drug-induced hair disorders. Review

Current drug safety 2006 43 件の引用

[Androgenetic alopecia]. Review

Revue medicale de … 2004

Topical minoxidil counteracts stress-induced hair growth inhibition in mice. Other

Experimental dermatology 2003 35 件の引用

Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Case Report

Archives of dermatology 2003 13 件の引用

Alopecia in women. Review

American family physician 2003 2 件の引用

Common hair loss disorders. Review

American family physician 2003

Causes of hair loss and the developments in hair rejuvenation. Other

International journal of … 2002 95 件の引用

[Diffuse hair loss in women]. Other

Therapeutische Umschau. Revue … 2002 4 件の引用

Therapeutic approaches to the management of common baldness. Review

International journal of … 1999 16 件の引用

Chronic telogen effluvium: potential complication for clinical trials in female androgenetic alopecia? Other

Journal of the … 1997 11 件の引用

Drug-induced hair loss and hair growth. Incidence, management and avoidance. Review

Drug safety 1994 137 件の引用

Management of hair loss in women. Review

Dermatologic clinics 1993 38 件の引用

Telogen effluvium and minoxidil. Case Report

Journal of the … 1989 21 件の引用

Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. Other

Journal of the … 1987 29 件の引用

A falling out following minoxidil: telogen effluvium. Case Report

Journal of the … 1987 4 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

topical:: 2-5% solution, twice daily

上限量： 5% topical solution

研究で検討された用量

用量	期間	効果	N
None	--	Neutral	--
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5	--	Positive	--
5% topical minoxidil lotion 1mL applied to entire scalp twice daily	24 weeks	Positive	12
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Positive	--
None	--	Positive	--

推奨摂取タイミング： Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

報告されている副作用

⚠ Scalp irritation and dryness
⚠ Initial shedding phase (first 2-8 weeks)
⚠ Unwanted facial hair growth (especially in women)
⚠ Dizziness or lightheadedness (rare with topical use)
⚠ Heart palpitations (rare, more common with oral form)

既知の相互作用

● Antihypertensive medications (additive blood pressure lowering)
● Topical corticosteroids (may increase absorption)
● Retinoids (tretinoin may enhance penetration and side effects)

耐容上限摂取量： 5% topical solution

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does ミノキシジル help with 休止期脱毛症?

Based on 66 studies with 20,942 participants, there is strong evidence from multiple clinical trials that ミノキシジル may support 休止期脱毛症 management. Our evidence grade is A (Strong Evidence).

How much ミノキシジル should I take for 休止期脱毛症?

Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of ミノキシジル?

Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for ミノキシジル and 休止期脱毛症?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 66 peer-reviewed studies with 20,942 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分：休止期脱毛症

ブラックシードオイル A ビビスカル A 鉄 B オメガ3脂肪酸 B ケラチン B 葉酸 B

ミノキシジル他の症状・状態について

男性型・女性型脱毛症（AGA） A 円形脱毛症 A 女性型脱毛症 A

総合評価

合計20,927名の参加者を対象とした52件の研究（メタアナリシス1件、RCT 1件を含む）に基づく。52件中39件の研究で肯定的な効果が示されている。

Evidence Strength92%

High confidence

研究の内訳

RCT (0)Meta (0)Other (66)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る：休止期脱毛症

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

ミノキシジル ： 休止期脱毛症

Embed This Widget

結論

Key Study Findings

Key Statistics

Referenced Papers

Dosage & Usage

一般的な使用量

研究で検討された用量

Safety & Side Effects

報告されている副作用

既知の相互作用

Frequently Asked Questions

Related Evidence

に関する他の成分： 休止期脱毛症

ミノキシジル 他の症状・状態について

ミノキシジル：休止期脱毛症

に関する他の成分：休止期脱毛症

ミノキシジル他の症状・状態について